These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 24166522

  • 1. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.
    J Clin Oncol; 2013 Dec 01; 31(34):4283-9. PubMed ID: 24166522
    [Abstract] [Full Text] [Related]

  • 2. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.
    J Clin Oncol; 2013 Dec 01; 31(34):4290-6. PubMed ID: 23630211
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH.
    Pharmacoeconomics; 2017 Apr 01; 35(4):425-438. PubMed ID: 27928760
    [Abstract] [Full Text] [Related]

  • 5. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC.
    J Clin Oncol; 2008 Jan 10; 26(2):290-6. PubMed ID: 18182670
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.
    Dtsch Med Wochenschr; 2010 Mar 10; 135(9):385-9. PubMed ID: 20180162
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH.
    J Med Econ; 2014 Jan 10; 17(1):32-42. PubMed ID: 24028444
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1078-85. PubMed ID: 23873405
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.
    Appl Health Econ Health Policy; 2013 Apr 07; 11(2):129-38. PubMed ID: 23435861
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM.
    J Clin Oncol; 2012 Apr 01; 30(10):1064-71. PubMed ID: 22393098
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T, Rayson D, Jovanovic S, Skedgel C.
    Breast Cancer Res Treat; 2016 Oct 01; 159(3):425-32. PubMed ID: 27572552
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.
    Curr Med Res Opin; 2011 Jan 01; 27(1):79-86. PubMed ID: 21091127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer.
    Jacobs VR, Augustin D, Wischnik A, Kiechle M, Höss C, Steinkohl O, Rack B, Kapitza T, Krase P.
    Breast; 2013 Aug 01; 22(4):436-43. PubMed ID: 23643802
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
    Danova M, Chiroli S, Rosti G, Doan QV.
    Tumori; 2009 Aug 01; 95(2):219-26. PubMed ID: 19579869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.